Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children

Ruth A. Karron; Jocelyn San Mateo; Bhagvanji Thumar; Anne Schaap-Nutt; Ursula J. Buchholz; Alexander C. Schmidt; Emmalene J. Bartlett; Brian R. Murphy; Peter L. Collins

doi:10.1093/jpids/piu104

Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children

Ruth A. Karron, Jocelyn San Mateo, Bhagvanji Thumar, Anne Schaap-Nutt, Ursula J. Buchholz, Alexander C. Schmidt, Emmalene J. Bartlett, Brian R. Murphy, Peter L. Collins

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: Adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.

Original language	English (US)
Pages (from-to)	e143-e146
Journal	Journal of the Pediatric Infectious Diseases Society
Volume	4
Issue number	4
DOIs	https://doi.org/10.1093/jpids/piu104
State	Published - Dec 1 2015

Keywords

Children
HPIV-1 vaccine
Lower respiratory tract illness

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Infectious Diseases

Access to Document

10.1093/jpids/piu104

Cite this

@article{940ce8e6b069493c96bf98cba65249b2,

title = "Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children",

abstract = "We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: Adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.",

keywords = "Children, HPIV-1 vaccine, Lower respiratory tract illness",

author = "Karron, {Ruth A.} and Mateo, {Jocelyn San} and Bhagvanji Thumar and Anne Schaap-Nutt and Buchholz, {Ursula J.} and Schmidt, {Alexander C.} and Bartlett, {Emmalene J.} and Murphy, {Brian R.} and Collins, {Peter L.}",

note = "Publisher Copyright: {\textcopyright} The Author 2014.",

year = "2015",

month = dec,

day = "1",

doi = "10.1093/jpids/piu104",

language = "English (US)",

volume = "4",

pages = "e143--e146",

journal = "Journal of the Pediatric Infectious Diseases Society",

issn = "2048-7207",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children

AU - Karron, Ruth A.

AU - Mateo, Jocelyn San

AU - Thumar, Bhagvanji

AU - Schaap-Nutt, Anne

AU - Buchholz, Ursula J.

AU - Schmidt, Alexander C.

AU - Bartlett, Emmalene J.

AU - Murphy, Brian R.

AU - Collins, Peter L.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: Adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.

AB - We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: Adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.

KW - Children

KW - HPIV-1 vaccine

KW - Lower respiratory tract illness

UR - http://www.scopus.com/inward/record.url?scp=85006201768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006201768&partnerID=8YFLogxK

U2 - 10.1093/jpids/piu104

DO - 10.1093/jpids/piu104

M3 - Article

C2 - 26582883

AN - SCOPUS:85006201768

SN - 2048-7207

VL - 4

SP - e143-e146

JO - Journal of the Pediatric Infectious Diseases Society

JF - Journal of the Pediatric Infectious Diseases Society

IS - 4

ER -

Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this